Journal profile · Medicine-Oncology
Cancer Biology & Medicine
ISSN 2095-3941 · Chinese Anticancer Association · China · Quarterly · Founded 2012
Cancer Biology & Medicine: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 13.92; fully open access; APC about USD 2,800; review about 12 weeks (community reports); 120 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Biology & Medicine is published by Chinese Anticancer Association and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and Cancer Genomics and Diagnostics, together about 22.7% of its articles. Its main subfields are Oncology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Biology & Medicine is dedicated to reporting latest advances in cancer research around the world by presenting high quality articles, especially on translational cancer research, to bridge the gap between bench and beside. Meanwhile, the journal promotes academic exchange in cancer area between China and the rest of the world to keep cancer researchers and clinicians updated with current knowledge of novel findings and recent advances in oncology. The scope covers the following topics:
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine12.2%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.3%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.3%
- Lung Cancer Treatments and MutationsMedicine5%
- Ferroptosis and cancer prognosisMedicine5%
- Immune cells in cancerImmunology and Microbiology4.7%
- Cancer Cells and MetastasisMedicine4.5%
- CAR-T cell therapy researchMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPMCEmbaseCASPublisher website
Other: BIOSIS Previews, EBSCO
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 13.92LetPub ·
- CiteScore 2026-06
- 11.5LetPub ·
- SJR 2026-06
- 1.89LetPub ·
- SNIP 2026-06
- 1.37LetPub ·
- h-index
- 29LetPub ·
- h-index
- 71OpenAlex ·
- i10-index
- 490OpenAlex ·
- 2-year mean citedness
- 5.27OpenAlex ·
- Self-citation rate
- 0.8%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 68LetPub ·
Articles by year OpenAlex count · 967 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 111 | 111 | 58 |
| 2025 | 120 | 120 | 524 |
| 2024 | 85 | 85 | 1,083 |
| 2023 | 95 | 95 | 1,549 |
| 2022 | 60 | 60 | 1,606 |
| 2021 | 154 | 154 | 4,044 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,800 / JPY 19,000 | No | CC BY-NC | |
| OpenAlex | USD 1,500 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≤ 5
- Reference style
- Numbered, in order of citation
- Cover letter
- Required
Article types accepted8
- editorialEditorials are comprised of commentary and analysis on the leading-edge discoveries in cancer research and significant advances in cancer diagnosis and treatmen…Length not stated
- letterLetters include significant and focused findings of original studies with characteristics of concise, novelty, and timely.Abstract or the structure of original …Length not stated
- letter to the editorReaders are encouraged to comment on articles published in Cancer Biology & Medicine, via Letters to the Editor. Letters to the editor will not undergo peer rev…Length not stated
- minireviewOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.Length not stated
- original articleOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.Length not stated
- perspectiveOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.Length not stated
- practice guidelineOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.Length not stated
- reviewReviews discuss recent progress on topics of broad interest to cancer researchers or cancer care professionals. Solicited reviews will also be sent out for peer…Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Self-archiving
- Authorship Authorship and Contributorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. The manuscript’s content and its submission for publication should be approved by all authors who should sig…
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
Conflict of interest disclosure required for all authors. Model summary
Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has any financial or personal relationships that may inappropriately influence (bias) his or her actions. Cancer Biology & Medicine requires all authors to disclose any relationship that might result in an actual, potential, or perceived conflict of interest about the manuscript submitted for review. Reviewe…
Source ↗Publisher website ·- Publication ethics Checking for Scientific Misconduct
Cancer Biology & Medicine has an obligation to ensure that its published articles are accurate and adheres to the highest ethical standard. Editors check all submissions using CrossCheck. In the cases of plagiarism, redundant or duplicate publication, the journal will send a letter of reprimand to the authors’ institution, publish a notice of misconduct and formally retract the published manuscrip…
Source ↗Publisher website ·- License & copyright Copyright and Permissions
If a manuscript includes copyrighted materials of others, authors must obtain written permission from the copyright owners and indicate the sources in the article. The written permission should be simultaneously submitted with the manuscript.
Source ↗Publisher website ·- Open access Open Access
Open access. Model summary
All articles published in Cancer Biology & Medicine are made freely and permanently available online immediately upon publication, without subscription charges or registration barriers.
Source ↗Publisher website ·- Peer review Peer Review
After initial review by the editor or sometimes by an editorial board member, manuscripts without sufficient priority for publication will be editorially rejected within 7 days. Those qualifying for peer review will be sent to at least two expert reviewers for unbiased, independent and critical assessment. Reviewers are asked to provide an overall recommendation supported by detailed comments on t…
Source ↗Publisher website ·- Self-archiving Embargo Policy
Scientific information in a manuscript which is under consideration or in press in Cancer Biology & Medicine may not be discussed with the media before publication. Preliminary reporting to public media, governmental agencies, or manufacturers should not jeopardize publication, and should be discussed with and approved by the editor in advance.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Chinese Anticancer Association
- Country or region
- China
- Language
- English
- Frequency
- Quarterly
- Founded
- 2012
- ISSN
- 2095-3941
- Latest issue on the website
- Volume 23, Issue 8 (August 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
FAQ
Frequently asked questions about Cancer Biology & Medicine
What CAS zone is Cancer Biology & Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Biology & Medicine is in Zone 2 of Medicine, and in Zone 2 of the minor category Medicine, Research & Experimental / Oncology. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Biology & Medicine?
The latest impact factor listed by LetPub is 13.92; CiteScore 11.5, h-index 71.
How long does peer review take at Cancer Biology & Medicine?
Authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Biology & Medicine?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≤ 5; Reference style: Numbered, in order of citation; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Cancer Biology & Medicine?
According to LetPub and DOAJ records, Cancer Biology & Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, PMC, Embase and CAS; that list has not been checked against each database.
Is Cancer Biology & Medicine open access, and what is the APC?
Cancer Biology & Medicine is a fully open-access journal. APC about USD 2,800.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .